---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-000132"
form_type: "8-K"
ticker: "LFWD"
cik: "0001607962"
company_name: "Lifeward Ltd."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:40:18.598898+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lifeward acquires Oramed's POD tech; Oramed gets up to 49.99% LFWD stake; up to $47M capital

## Summary
- Issues Oramed shares & pre-funded warrants for 49.99% fully diluted equity (max 45% post-closing).
- Up to $47M from Oramed & another investor via $20M convertible notes (8% interest, 100% warrant coverage) and equity.
- Oramed to receive 4% of ReWalk net sales for up to 10 yrs; board expands to 6 (2 each from LFWD, Oramed, 2 external).
- Oramed funds/manages POD clinical program; $10M note funded at close, second $10M conditional on revenue or share price milestone.
- Transaction subject to shareholder approval; 120-day lock-up for officers, directors, and Oramed shares.

## SEC filing metadata
- accession: 0001178913-26-000132
- form_type: 8-K
- ticker: LFWD
- cik: 0001607962
- company_name: Lifeward Ltd.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/0001178913-26-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/zk2634192.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-000132
- JSON: https://secwatch.observer/filing/0001178913-26-000132.json
- Plain text: https://secwatch.observer/filing/0001178913-26-000132.txt

## Key facts
- Material Agreements
  Lifeward Ltd. entered into Share Purchase Agreement with Oramed Pharmaceuticals, Inc. (effective 2026-01-12).
  - Action: entry
  - Agreement: merger
  - Counterparty: Oramed Pharmaceuticals, Inc.
  - Effective: 2026-01-12
  source text: On January 12, 2026, Lifeward Ltd. (the “Company,” “we” or “us”) entered into a Share Purchase Agreement (“Share Purchase Agreement”) with Oramed Pharmaceuticals, Inc. (“Oramed”) and Oratech Pharma, Inc. (“Oratech”) pursuant to which the Company agreed to acquire all of the outstanding equity interests in Oratech, a wholly owned subsidiary of Oramed (the “Oratech Share Purchase”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/0001178913-26-000132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.